Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback